In this segment, Dr. Shore will offer an overview of current treatment options for metastatic hormone-sensitive prostate cancer (mHSPC), as outlined in the NCCN Guidelines for Prostate Cancer. He will discuss patient factors that guide the selection of therapeutic agents or combination therapies.
Dr. Shore will provide his initial impressions of the patient case, including an assessment of the patient's risk level and how this influences clinical decision-making.
The panel gives an overview of adjuvant immunotherapy options for patients with renal cell carcinoma.
Sumanta Kumar Pal, MD, FASCO, presents the case of a 48-year-old man with renal cell carcinoma, and Rana R. McKay, MD, discusses how she discusses risk of recurrence with patients.
The final segment explores the potential role of axatilimab, a novel agent, in the management of refractory cGvHD, highlighting its mechanism of action and potential efficacy compared to existing treatment options.
Yi-Bin Chen, MD, proposes a strategy to enhance patients' quality of life by utilizing virtual monitoring as an alternative to requiring patients to travel to a transplant center, which includes regular remote assessments of blood work, such as liver function tests, lipid panels, and immunoglobulin levels.
A medical expert delves into various aspects of second-line therapies, including dose reductions, potential adverse reactions, and the possibility of transfusions, all of which are important considerations when managing patients on second-line treatments.
Arvind Dasari, MD, explores the adverse event profile of Fruquintinib, highlighting its apparent tolerability, while emphasizing the importance of gathering real-world data to further assess the adverse event profile of this medication in clinical practice.
Medical professionals provide background on the FRESCO-2 trial, which compared Fruquintinib to placebo in patients with heavily pretreated metastatic colorectal cancer. The trial enrolled patients who had exhausted all standard treatment options, including cytotoxic chemotherapy, targeted therapies, anti-VEGF agents, and BRAF inhibitors for those with BRAF mutations.
Anne O’Dea, MD, discusses factors that contribute to second-line treatment selection and offers clinical insights on improving outcomes for patients being treated for breast cancer.
Expert perspectives on safety data from the EMERALD subgroup analysis, highlighting endocrine therapy–related adverse effects and supportive care strategies.
Dr O’Dea provides an overview of the EMERALD trial investigating elacestrant in patients with ER+/HER2- advanced breast cancer and discusses subgroup analysis data and their clinical implications.
A hematologist-oncologist discusses the importance of biomarker testing in breast cancer, provides clinical insights on how to prioritize different testing assays, and outlines the roles of circulating tumor DNA and repeat testing.
Anne P. O'Dea, MD, presents the case of a 49-year-old woman with HR+/HER2- metastatic breast cancer and offers initial impressions on the patient’s risk and prognosis.
Yi-Bin Chen, MD, provides an overview of the iNTEGRATE and ROCKstar trials, underscoring their significance in the current treatment paradigm for graft versus host disease, particularly highlighting their ability to inhibit the fibrosis cascade, which offers substantial benefits for patient healing and recovery.
Yi-Bin Chen, MD, presents the results of the phase-3 randomized REACH-3 Trial, highlighting the superior best overall response rate of 75% in the experimental arm compared to 60% in the best-available therapy arm.
This segment delves into the management of a case of moderate cGvHD involving the skin, eyes, and mouth, with a focus on the use of Belumosudil based on the ROCKstar trial data.
This segment delves into the management of a case of moderate cGvHD involving the skin, eyes, and mouth, with a focus on the use of Belumosudil based on the ROCKstar trial data.
Rebecca A. Shatsky, MD, looks to the future of HER2+ breast cancer treatment, highlighting unmet needs in the therapeutic space.
A medical professional outlines the goals and challenges of communicating with his patient, emphasizing the importance of setting realistic expectations for halting disease progression and potentially achieving some degree of disease reversibility, while also exploring the roles of first-line and second-line therapies in the management of chronic graft versus host disease.
Yi-Bin Chen, MD, presents a patient case, detailing the symptomology and pathology of graft versus host disease, such as dry eyes, dry mouth, and difficulty swallowing, while also addressing steroid dependence as an indication for initiating second-line therapy.
Dr Shatsky provides clinical insights on treatment sequencing for patients undergoing treatment for HER2-positive breast cancer.
An expert on HER2+ breast cancer discusses exciting advancements in the treatment landscape, highlighting the DESTINY-Breast03 trial and trastuzumab deruxtecan.
Rebecca A. Shatsky, MD, discusses the KATHERINE trial investigating adjuvant trastuzumab emtansine (T-DM1) in patients with residual invasive HER2+ breast cancer following neoadjuvant therapy.
Dr Shatsky discusses pertuzumab as a treatment for patients with HER2+ breast cancer, highlighting its mechanism of action as a HER2 dimerization inhibitor and updated data from the APHINITY trial.
Dr. McCloskey discusses the limitations of current treatment options for BPDCN, as well as the emerging research and data that are most anticipated in the field.
Dr. McCloskey explores how various treatments for BPDCN impact the quality of life of patients, both in terms of disease response and side effects.
Dr. McCloskey discusses the general principles and practices for monitoring and mitigating adverse events, particularly capillary leak syndrome (CLS), in BPDCN patients treated with systemic agents like tagraxofusp.
Dr. McCloskey examines the potential of anti-CD123 CAR T-cell therapy for BPDCN, including the main challenges and limitations of this therapeutic approach.
Dr. McCloskey discusses the recent clinical trial results, such as the CADENZA trial, on the efficacy and safety of tagraxofusp in BPDCN patients.